The Cooper Companies
COO
$71.02
+2.03%
The Cooper Companies, Inc. is a leading global eyecare and women's health company operating through two segments: CooperVision, a pure-play contact lens business with a comprehensive portfolio including Biofinity and MyDay, and CooperSurgical, which provides medical devices for reproductive health and fertility. As the second-largest contact lens manufacturer in the U.S., Cooper controls roughly one-fourth of the domestic contact lens market and holds a 17% share of the U.S. IUD market with its hormone-free Paragard device. The current investor narrative centers on the company's steady revenue growth driven by its contact lens segment and expanding surgical offerings, while margin pressures and a recent stock pullback from 52-week highs have sparked debate about valuation support and the sustainability of its growth trajectory.…
COO
The Cooper Companies
$71.02
Related headlines
COO 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cooper Companies's 12-month outlook, with a consensus price target around $92.33 and implied upside of +30.0% versus the current price.
Average Target
$92.33
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$57 - $92
Analyst target range
The stock is covered by 5 analysts, with a consensus leaning bullish: ratings include 2 Buys (Needham, Stifel), 1 Overweight (Barclays), 1 Neutral (Citigroup), 1 Equal Weight (Morgan Stanley), and 1 Sell (Goldman Sachs). The average estimated EPS for the current fiscal year is $5.95, with a range of $5.91 to $5.99. Based on the current price of $74.20, the implied forward P/E of 12.5x (using average EPS) suggests significant upside if the consensus is correct. However, no explicit price targets are provided in the data. The range of analyst estimates is narrow (EPS range $5.91-$5.99), indicating high conviction in near-term earnings. Recent ratings actions show stability: Citigroup, Needham, and Barclays maintained their ratings in March 2026, while Goldman Sachs and Morgan Stanley held Sell and Equal Weight since December 2025. The absence of price targets limits the ability to calculate implied upside, but the strong earnings growth expected (forward P/E of 14.9x vs. trailing 37.2x) suggests the market anticipates a significant earnings recovery, which could drive the stock higher if realized.
Drowning in data?
Find the real signal!
COO Technical Analysis
The stock is in a clear downtrend over the past year, with a 1-year price change of +1.6% significantly underperforming the S&P 500's +19.1% gain. Currently trading at $74.20, the stock sits at 82.6% of its 52-week range ($58.89 low to $89.83 high), indicating it has recovered from its lows but remains well below the highs. This positioning suggests the stock is in a recovery phase but has not yet regained bullish momentum, as it remains 17.4% below the 52-week high. Short-term momentum has improved markedly, with a 1-month price change of +24.7% versus a 3-month change of +5.7%, showing accelerating recovery from the April lows. However, the 1-year trend remains weak, and the relative strength versus the S&P 500 is negative across all timeframes (1-month relative strength +26.0%, but 1-year relative strength -17.5%), indicating the stock is still lagging the broader market on a longer-term basis. The 52-week low of $58.89 provides strong support, while the 52-week high of $89.83 represents key resistance. A breakout above $89.83 would signal a reversal of the downtrend, while a breakdown below $58.89 could trigger further selling. With a beta of 0.84, the stock is less volatile than the market, meaning it tends to decline less in downturns but also rallies less in up markets, which is consistent with its defensive healthcare profile.
Beta
0.84
0.84x market volatility
Max Drawdown
-30.1%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-5.2%
Cumulative gain past year
| Period | COO Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | +2.0% |
| 3m | -0.3% | +10.6% |
| 6m | -14.9% | +8.3% |
| 1y | -5.2% | +20.4% |
| ytd | -12.4% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COO Fundamental Analysis
Revenue has grown steadily, with the most recent quarter (Q1 2026) reporting $1.024 billion, up 6.2% year-over-year from $964.7 million in Q1 2025. The multi-quarter trend shows consistent growth: Q2 2025 revenue was $1.002 billion, Q3 2025 was $1.060 billion, and Q4 2025 was $1.065 billion, indicating a stable mid-single-digit growth trajectory. Segment data reveals CooperVision contributed $695.1 million (68% of total) and CooperSurgical $329.0 million (32%), with the contact lens business being the primary growth driver. The company is profitable, with net income of $130.8 million in Q1 2026 and a gross margin of 67.9%, which is healthy for the medical instruments industry. However, operating margin has compressed from 19.4% in Q4 2024 to 20.8% in Q1 2026, while net margin improved to 12.8% from 11.5% a year ago, indicating stable profitability with slight expansion. The balance sheet is solid, with a debt-to-equity ratio of 0.34 and a current ratio of 1.89, indicating ample liquidity. Free cash flow was $158.7 million in Q1 2026, up from $101.2 million in Q1 2025, and the trailing twelve-month free cash flow is $491.2 million, providing strong internal funding for growth. Return on equity is 4.6%, which is modest but improving from 1.3% in Q1 2025, reflecting better capital efficiency.
Quarterly Revenue
$1.0B
2026-01
Revenue YoY Growth
+6.16%
YoY Comparison
Gross Margin
67.88%
Latest Quarter
Free Cash Flow
$491200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COO Overvalued?
Since net income is positive ($130.8 million), the primary valuation metric is the P/E ratio. The trailing P/E is 37.2x, while the forward P/E is 14.9x, implying the market expects significant earnings growth in the coming year. The large gap between trailing and forward P/E suggests that current earnings are depressed (likely due to one-time items or cyclical factors) and that analysts anticipate a sharp rebound. Compared to the industry (Medical - Instruments & Supplies), the stock's trailing P/E of 37.2x is above the sector average of approximately 25x, representing a 49% premium. However, the forward P/E of 14.9x is below the industry average of 18x, suggesting that if earnings materialize as expected, the stock could be undervalued relative to peers. Historically, the stock's trailing P/E has ranged from 30x to 57x over the past two years, and the current 37.2x is near the lower end of that range, indicating that the stock is trading at a discount to its own historical valuation. This could imply that the market is pricing in cautious expectations, but the low forward multiple suggests potential upside if the company delivers on earnings forecasts.
PE
37.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~119x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.8x
Enterprise Value Multiple
